Landmark FDA approval of Cobenfy represents the first new class of drugs indicated to treat schizophrenia in decades.
FDA Approves Bristol Myers Squibb’s Cobenfy for Schizophrenia
Landmark FDA approval of Cobenfy represents the first new class of drugs indicated to treat schizophrenia in decades.
